---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-097992"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2025-10-08T23:59:59+00:00"
generated_at: "2026-05-17T04:18:23.844850+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Esperion prices $75M public offering of 30M shares at $2.50 each

## Summary
- Offering of 30,000,000 shares at $2.50/share; net proceeds ~$70.2M (or ~$80.7M if underwriters' option exercised).
- Expected close October 9, 2025; use proceeds for NEXLETOL/NEXLIZET commercialization, R&D, working capital.
- Piper Sandler & Cantor Fitzgerald are joint book-running managers; co-managers include Citizens JMP, H.C. Wainwright, Needham.
- Shares sold under existing shelf registration statement (File No. 333-286631) effective April 29, 2025.

## SEC filing metadata
- accession: 0001104659-25-097992
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2025-10-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000110465925097992/0001104659-25-097992-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000110465925097992/tm2527818d4_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-097992
- JSON: https://secwatch.observer/filing/0001104659-25-097992.json
- Plain text: https://secwatch.observer/filing/0001104659-25-097992.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.